NZ722768A - Use of alphavirus in preparation of antitumor drugs - Google Patents

Use of alphavirus in preparation of antitumor drugs

Info

Publication number
NZ722768A
NZ722768A NZ722768A NZ72276815A NZ722768A NZ 722768 A NZ722768 A NZ 722768A NZ 722768 A NZ722768 A NZ 722768A NZ 72276815 A NZ72276815 A NZ 72276815A NZ 722768 A NZ722768 A NZ 722768A
Authority
NZ
New Zealand
Prior art keywords
alphavirus
preparation
antitumor drugs
virus
antitumor
Prior art date
Application number
NZ722768A
Other languages
English (en)
Inventor
Guangmei Yan
Xiao Xiao
Jun Hu
Kai Li
Jiankai Liang
Yuan Lin
Haipeng Zhang
Suizhen Lin
Original Assignee
Guangzhou Virotech Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Virotech Pharmaceutical Co Ltd filed Critical Guangzhou Virotech Pharmaceutical Co Ltd
Priority to NZ74633815A priority Critical patent/NZ746338A/en
Publication of NZ722768A publication Critical patent/NZ722768A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
NZ722768A 2014-08-26 2015-08-24 Use of alphavirus in preparation of antitumor drugs NZ722768A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ74633815A NZ746338A (en) 2014-08-26 2015-08-24 Use of alphavirus and zap inhibitor in the preparation of an antitumor drug, and antitumor drugs comprising the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410425510.3A CN104814984B (zh) 2014-08-26 2014-08-26 甲病毒在制备抗肿瘤药物方面的应用
PCT/CN2015/087945 WO2016029833A1 (zh) 2014-08-26 2015-08-24 甲病毒在制备抗肿瘤药物方面的应用

Publications (1)

Publication Number Publication Date
NZ722768A true NZ722768A (en) 2018-09-28

Family

ID=53725628

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ722768A NZ722768A (en) 2014-08-26 2015-08-24 Use of alphavirus in preparation of antitumor drugs
NZ74633815A NZ746338A (en) 2014-08-26 2015-08-24 Use of alphavirus and zap inhibitor in the preparation of an antitumor drug, and antitumor drugs comprising the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ74633815A NZ746338A (en) 2014-08-26 2015-08-24 Use of alphavirus and zap inhibitor in the preparation of an antitumor drug, and antitumor drugs comprising the same

Country Status (16)

Country Link
US (2) US10517909B2 (de)
EP (1) EP3187588B1 (de)
JP (2) JP6441372B2 (de)
KR (2) KR102125602B1 (de)
CN (3) CN104814984B (de)
AU (1) AU2015309403B2 (de)
CA (1) CA2939535C (de)
HK (1) HK1212925A1 (de)
IL (1) IL247082B2 (de)
MX (1) MX2016010058A (de)
MY (1) MY188734A (de)
NZ (2) NZ722768A (de)
RU (1) RU2693938C2 (de)
SG (1) SG11201606707RA (de)
TW (1) TWI609690B (de)
WO (1) WO2016029833A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104814984B (zh) 2014-08-26 2017-09-15 广州威溶特医药科技有限公司 甲病毒在制备抗肿瘤药物方面的应用
CN105233285B (zh) * 2015-09-06 2018-10-12 广州威溶特医药科技有限公司 Epac直接或间接激动剂与溶瘤病毒的联合应用
CN105456302B (zh) * 2015-12-23 2019-09-24 广州威溶特医药科技有限公司 大黄酚或其衍生物和溶瘤病毒在制备抗肿瘤药物的应用
CN106177955B (zh) * 2016-08-18 2018-03-16 广州威溶特医药科技有限公司 Bcl‑xL抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用
CN106177961B (zh) * 2016-08-18 2018-03-13 广州威溶特医药科技有限公司 Vcp抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用
CN106265764B (zh) 2016-08-18 2018-03-16 广州威溶特医药科技有限公司 Iap抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用
CN109207491A (zh) * 2017-07-05 2019-01-15 中国科学院武汉物理与数学研究所 一种m1病毒全长感染性克隆及制备方法及其在制备m1病毒中的应用
CN109985239B (zh) * 2017-12-29 2024-10-18 广州威溶特医药科技有限公司 极光激酶抑制剂和甲病毒在制备抗肿瘤药物的应用
CN109985241B (zh) * 2017-12-29 2024-10-18 广州威溶特医药科技有限公司 Cdk抑制剂和溶瘤病毒在制备抗肿瘤药物的应用
CN109985242B (zh) * 2017-12-29 2022-07-29 广州威溶特医药科技有限公司 甲羟戊酸代谢通路抑制剂和甲病毒在制备抗肿瘤药物的应用
CN109985244A (zh) * 2017-12-29 2019-07-09 广州威溶特医药科技有限公司 E3连接酶抑制剂和溶瘤病毒在制备抗肿瘤药物的应用
CN108635584B (zh) * 2018-05-22 2021-12-21 广州威溶特医药科技有限公司 蛋白酶体抑制剂和甲病毒在制备抗肿瘤药物中的应用
CN108686221B (zh) * 2018-07-25 2022-02-22 广州威溶特医药科技有限公司 增效的抗肿瘤药物
AU2020285291A1 (en) * 2019-05-31 2022-01-27 Guangzhou Virotech Pharmaceutical Co., Ltd. M1 virus mutant and use thereof
CN111632146B (zh) * 2020-05-29 2021-09-28 中山大学 Oat抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用
CN111603562A (zh) * 2020-05-29 2020-09-01 中山大学 5-脂氧合酶抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用
CN111544595B (zh) * 2020-05-29 2021-10-26 中山大学 泛素结合酶e2抑制剂和溶瘤病毒在制备抗肿瘤药物的应用
TWI778375B (zh) * 2020-06-18 2022-09-21 大陸商廣州威溶特醫藥科技有限公司 M1病毒變異體及其應用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2337905A1 (en) * 1998-07-30 2000-03-02 Johns Hopkins University School Of Medicine Targeted alphavirus and alphaviral vectors
US6998391B2 (en) * 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
MXPA05013190A (es) * 2003-06-06 2007-05-23 Arborgen Llc Factores de transcripcion.
CA2627638A1 (en) 2005-10-28 2007-05-03 Michael James Mathis Conditionally replicating viruses and methods for cancer virotherapy
CN105769931B (zh) * 2006-09-15 2021-04-27 渥太华医院研究机构 溶瘤弹状病毒
EE05462B1 (et) 2007-08-31 2011-08-15 Tartu �likool Meetod viiruse genoomse raamatukogu moodustamiseks, viiruse genoomne raamatukogu ja komplekt selle moodustamiseks
US8435961B2 (en) 2009-06-26 2013-05-07 Massachusetts Institute Of Technology Methods and compositions for increasing the activity of inhibitory RNA
AU2010329551B2 (en) 2009-12-10 2016-02-11 Turnstone Limited Partnership Oncolytic rhabdovirus
CN104138375A (zh) 2013-05-08 2014-11-12 南开大学 苯并吡啶类衍生物在制备抗hiv药物中的用途
CN104814984B (zh) * 2014-08-26 2017-09-15 广州威溶特医药科技有限公司 甲病毒在制备抗肿瘤药物方面的应用

Also Published As

Publication number Publication date
CN104814984A (zh) 2015-08-05
CN107349226B (zh) 2020-08-25
MY188734A (en) 2021-12-27
JP6441372B2 (ja) 2018-12-19
CN104814984B (zh) 2017-09-15
AU2015309403A1 (en) 2016-08-18
KR20180119706A (ko) 2018-11-02
US10517909B2 (en) 2019-12-31
EP3187588A1 (de) 2017-07-05
WO2016029833A1 (zh) 2016-03-03
TW201615202A (zh) 2016-05-01
EP3187588A4 (de) 2018-01-10
CN107456463A (zh) 2017-12-12
CA2939535A1 (en) 2016-03-03
US20200085892A1 (en) 2020-03-19
IL247082A0 (en) 2016-09-29
TWI609690B (zh) 2018-01-01
EP3187588B1 (de) 2020-11-18
RU2016131756A (ru) 2018-02-07
KR102125602B1 (ko) 2020-06-23
SG11201606707RA (en) 2016-09-29
CA2939535C (en) 2020-07-21
IL247082B2 (en) 2023-11-01
US11235011B2 (en) 2022-02-01
AU2015309403B2 (en) 2017-03-16
IL247082B1 (en) 2023-07-01
CN107349226A (zh) 2017-11-17
KR20160105523A (ko) 2016-09-06
JP2019048863A (ja) 2019-03-28
MX2016010058A (es) 2017-04-27
HK1212925A1 (zh) 2016-06-24
CN107456463B (zh) 2022-10-14
US20170304380A1 (en) 2017-10-26
RU2693938C2 (ru) 2019-07-08
NZ746338A (en) 2019-10-25
JP2017526612A (ja) 2017-09-14

Similar Documents

Publication Publication Date Title
NZ722768A (en) Use of alphavirus in preparation of antitumor drugs
MX2023000320A (es) Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion.
MX2021008224A (es) Combinacion de vacunacion e inhibicion de la trayectoria pd-1.
MX2022009352A (es) Sal de hemisulfato de nucleotido para el tratamiento del virus de hepatitis c.
PH12015501552A1 (en) Androgen receptor modulator and uses thereof
MY187540A (en) Compounds active towards bromodomains
EP3233165A4 (de) Sicherheitsspritze und verfahren zur verabreichung einer medikamentendosis nach dem gewicht einer person
SG11201609014TA (en) Gpc3 -targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
MX2016014414A (es) Vacuna de peptido que comprende un peptido ras mutante y un agente quimioterapeutico.
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
MX2016006544A (es) Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MY197664A (en) Immunity enhancing agent for cancer by allergin-1 antagonist
MX2018011607A (es) Sultiame para el tratamiento de apnea del sueño.
MX2017001512A (es) Compuestos activos hacia bromodominios.
PH12014502497A1 (en) New treatments of hepatitis c virus infection
UA84284U (ru) Способ лечения мононуклеоза у взрослых больных
UA112089C2 (uk) Тверда лікарська форма комбінованого препарату седативної та снодійної дії, що містить доксиламін
UA88769U (uk) Спосіб профілактики та лікування доброякісних дисплазій молочних залоз у жінок з ранніми втратами вагітності

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 AUG 2020 BY CATALYST INTELLECTUAL PROPERTY

Effective date: 20190717

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 AUG 2021 BY CATALYST INTELLECTUAL PROPERTY

Effective date: 20200730

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 AUG 2022 BY CATALYST INTELLECTUAL PROPERTY

Effective date: 20210726

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 AUG 2023 BY CATALYST INTELLECTUAL PROPERTY LIMITED

Effective date: 20220803

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 AUG 2024 BY CATALYST INTELLECTUAL PROPERTY LIMITED

Effective date: 20230803

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 AUG 2025 BY CATALYST INTELLECTUAL PROPERTY LIMITED

Effective date: 20240820